Test Catalog

Test Id : FIBAG

Fibrinogen Antigen, Plasma

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluation of fibrinogen deficiency

 

Measuring fibrinogen in patients with elevated plasma levels of fibrin degradation products, patients receiving heparin, and in patients with antibodies to thrombin (following surgical use of topical bovine thrombin)

 

Identifying afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia when ordered in combination with fibrinogen activity (FIBTP / Fibrinogen, Plasma)

Method Name
A short description of the method used to perform the test

Immunoturbidimetric

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Fibrinogen Antigen, P

Aliases
Lists additional common names for a test, as an aid in searching

FIBAG

Fibrinogen protein

Fibrinogen mass

Fibrinogen concentration

Specimen Type
Describes the specimen type validated for testing

Plasma Na Cit

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube: Light-blue top (3.2% sodium citrate at 9:1 ratio)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot plasma into plastic vial. Send refrigerated.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.5 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Plasma Na Cit Refrigerated (preferred) 14 days
Frozen 30 days
Ambient 72 hours

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluation of fibrinogen deficiency

 

Measuring fibrinogen in patients with elevated plasma levels of fibrin degradation products, patients receiving heparin, and in patients with antibodies to thrombin (following surgical use of topical bovine thrombin)

 

Identifying afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia when ordered in combination with fibrinogen activity (FIBTP / Fibrinogen, Plasma)

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Fibrinogen (clotting factor I) is an essential protein responsible for blood clot formation. In the final step of the coagulation cascade, thrombin converts soluble fibrinogen into insoluble fibrin strands that crosslink and form a clot.

 

Fibrinogen is synthesized in the liver and has a biological half-life of 3 to 5 days in the circulating plasma. Fibrinogen deficiencies can be congenital or acquired and lead to prolonged coagulation times. Isolated fibrinogen deficiency is an extremely rare inherited coagulation disorder.

 

Acquired fibrinogen deficiency is most commonly caused by, acute or decompensated intravascular coagulation and fibrinolysis. Other causes of fibrinogen deficiency include advanced liver disease, L-asparaginase therapy, or fibrinolytic agents (eg, streptokinase, urokinase, tissue plasminogen activator).

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =18 years: 196-441 mg/dL

Reference values have not been established for patients that are less than 18 years of age.

Interpretation
Provides information to assist in interpretation of the test results

This method measures the total amount of fibrinogen protein (ie, fibrinogen antigen) present in the plasma.

 

Adequate fibrinogen antigen levels in a context of low fibrinogen activity suggests a dysfibrinogenemia.

 

Fibrinogen antigen levels lower than 100 mg/dL are associated with an increased risk of bleeding.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Differentiation of congenital from acquired defects of fibrinogen requires clinical correlation and the results of standard clotting-based fibrinogen activity (FIBTP / Fibrinogen, Plasma) testing.

 

Fibrinogen is an acute phase reactant; plasma levels can be increased by inflammatory illnesses, nephrotic syndrome, liver disease, pregnancy, estrogen therapy, and/or compensated intravascular coagulation.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585-595

2. Mackie I, Casini A, Pieters M, Purthi R, Reilly-Stitt C, Suzuki A. International council for standardisation in haematology recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders. Int J Lab Hematol. 2024;46(1): 20-32. doi:10.1111/ijlh.14201

Method Description
Describes how the test is performed and provides a method-specific reference

The K-ASSAY Fibrinogen test analyzes the quantitative determination of fibrinogen in human plasma by immunoturbidimetric analysis. Samples and antibody reagent are automatically pipetted into individual cuvettes. Following an initial incubation and measurement of sample blank, antiserum is added to the cuvettes. The sample (antigen) solution and antiserum are then mixed in the reaction cuvettes. Insoluble antigen-antibody complexes form. The immune complexes cause an increase in light scattering, which correlates with the concentration of plasma fibrinogen. The absorbance of the solution is measured. (Package insert: K-ASSAY Fibrinogen. Kamiya Biomedical Company; 03/2023)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Sunday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

1 day

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

7 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

85385

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
FIBAG Fibrinogen Antigen, P 3256-5
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
FIBAG Fibrinogen Antigen, P 3256-5

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | PHP Pdf | CMS Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports